Tumor- and treatment-related side effects after multimodal therapy of childhood intracranial germ cell tumors.
Multimodality treatment approaches have dramatically improved the outcome of patients with intracranial germ cell tumors and are resulting in an increasing number of long-term survivors. The aim of the present study was to evaluate prospectively the development of side effects in children, adolescents and young adults after treatment for intracranial germ cell tumors. Nine patients with a median age of 14 y at diagnosis and a median follow-up of 7.25 y underwent a detailed long-term evaluation including physical and neuro-ophthalmologic examinations, routine laboratory and endocrine stimulation tests, neuropsychometric testing, audiometry and spirometry at repeated intervals. Endocrine deficiencies requiring hormone replacement therapy occurred in all patients. Neuro-ophthalmologic side effects were observed in 8 of the 9 patients, urinary electrolyte wasting in 4 of the 9, alopecia in 3 of the 9 and high-frequency hearing loss in 2 of the 9. Neuropsychologic examinations revealed pathologic results in all five tested patients.


CONCLUSIONS
The present study indicates that former intracranial germ cell tumor patients suffer from remarkable long-term side effects, and that some of these late effects can develop or worsen months or years after cessation of oncologic therapy. Since life quality is an important parameter of cancer survival, careful follow-up of long-term survivors is mandatory, aimed at counteracting side effects as early as possible and therefore at minimizing long-term morbidity, which may considerably compromise quality of life.
Benesch
M
M
Division of Paediatric Haematology and Oncology, University of Graz, Austria. martin.benesch@klinikum-graz.at
Lackner
H
H
Schagerl
S
S
Gallistl
S
S
Frey
E M
EM
Urban
C
C
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects; D001932:Brain Neoplasms / Q000628:therapy*; D002648:Child; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects; D003638:Deafness / Q000175:diagnosis / Q000209:etiology; D002658:Developmental Disabilities / Q000175:diagnosis / Q000209:etiology*; D004700:Endocrine System Diseases / Q000175:diagnosis / Q000209:etiology; D005128:Eye Diseases / Q000175:diagnosis / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy*; D009483:Neuropsychological Tests; D011446:Prospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents